Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472665 | 0.80 | TSHR (0.56) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL1702849 | 0.80 | MAPK1 (0.56) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL4485881 | 0.80 | ALDH1A1 (0.56) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL9791325 | 0.79 | EGFR (0.56) | TSHRCA1CA2LMNAALDH1A1 | |
| SCHEMBL19048616 | 0.78 | TDP1 (0.47) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL7918197 | 0.77 | CES1 (0.61) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL4468183 | 0.76 | ESR1 (0.57) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL8125164 | 0.76 | MAPK1 (0.47) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL1319438 | 0.76 | MAPT (0.48) | TDP1TSHRCES1CA1CA2 | |
| SCHEMBL4399847 | 0.76 | CES1 (0.53) | TDP1TSHRCES1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184525-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3184525-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3184525-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184525-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2797916-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013101954-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013101954-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TDP1 613/4885TSHR 2014/4885CES1 2125/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | TDP1 787/4885TSHR 1514/4885CES1 2942/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TDP1 613/4885TSHR 2014/4885CES1 2125/4885 |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | REN, JAK2, FGFR1 | TDP1 3921/4885TSHR 618/4885CES1 3343/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | TDP1 653/4885TSHR 2171/4885CES1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.